Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Levofloxacin (Primary) ; Antituberculars
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- Acronyms Opti-Q
- 26 Feb 2018 Status changed from completed to active, no longer recruiting.
- 26 Feb 2018 Planned End Date changed from 1 Aug 2017 to 1 Mar 2019.
- 26 Feb 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Mar 2019.